MucofanTM

Oral mucositis is a severely debilitating condition characterized by erythema, edema, and ulcerations of the oral mucosa. 

It is a complication of radiation therapy (RT) to the head and neck, chemotherapy, chemoradiotherapy, and hematopoeitic stem cell transplantation (HSCT). 

Oral intake may be impaired due to pain, which in some cases may lead to the need for parenteral nutrition. In addition, the oral lesions weaken the mucosa barrier resulting in local or systemic infection. 

In severe oral mucositis caused by chemotherapy, the dose in the subsequent chemotherapy cycle may have to be decreased or delayed, affecting patients’ quality of life and worsening prognosis.

WHO Oral Toxicity Scale

World Health Organization Oral Toxicity Scale measures the anatomical, symptomatic, and functional elements of Oral Mucositis. The scale is:

Oral Mucositis – Current Treatment Options

Patients with Oral Mucositis currently have very limited treatment options and the available products offer only symptomatic relief, if any.

MUCOFAN™

MUCOFAN™ is a unique, proprietary product which helps minimize oral lesions (Oral Mucositis) in patients prior to the start of Radiotherapy and Chemotherapy. In addition, MUCOFAN™ also helps treat the existing oral lesions associated with Oral Mucositis due to Radiotherapy and Chemotherapy, thus significantly improving the radio and chemotherapy outcomes and improving quality of life of the patients.

MUCOFAN™ - Mode of Action

MUCOFAN™ lozenges / chew tablets contain Lactobacillus brevis strain CD2, which has been proven to attenuate the inflammatory processes through activities of its unique enzymes (in particular, Arginine Deiminase).  Arginine Deiminase from Lactobacillus brevis competes for Arginine with inducible Nitric Oxide Synthase (iNOS) to reverse the metabolism of arginine into ammonia (NH3) and citrulline resulting in down regulation of Nitric Oxide (NO) and polyamine synthesis.  By downregulating Nitric Oxide and Polyamine levels, MUCOFAN™ has shown strong anti-inflammatory effects for conditions such as radiotherapy and/or chemotherapy induced oral mucositis in cancer patients and in patients undergoing hematopoietic stem cell transplant (HSCT).

MUCOFAN™ - Composition

Each MUCOFAN™ lozenge contains not less than 2 billion CFU of live, lyophilized lactic acid bacteria, Lactobacillus brevis CD2.

MUCOFAN™ is indicated for the prevention of radiotherapy and chemotherapy induced oral mucositis in patients undergoing anticancer therapy.